← All indications
Vulvar Neoplasms
Tumors or cancer of the VULVA.
Drugs by status
Phase 4 trials (3)
Phase 3 trials (6)
Phase 2 trials (53)
- ino-3112
- metformin
- fluorothymidine
- atezolizumab
- antineoplaston a10
- artemisinin
- avelumab
- cefazolin
- doxorubicin
- durvalumab
- e7 tcr transduced pbl cells
- entinostat
- gemcitabine
- paclitaxel
- aldesleukin
- nivolumab
- bleomycin
- irx-2
- pembrolizumab
- lenvatinib
- methyl aminolevulinate
- omiganan
- fondaparinux sodium
- phenylacetic acid
- indomethacin
- ipilimumab
- carboplatin
- interleukin-12
- cyclophosphamide
- bevacizumab
- +23 more
Phase 1 trials (25)
- decitabine
- hpv specific t cells
- artesunate
- ganciclovir
- trastuzumab
- solamargine
- topotecan
- tremelimumab
- triapine
- human papillomavirus 16 e7 peptide
- synthetic human papillomavirus 16 e6 peptide
- v502
- docetaxel
- nelfinavir
- perflubutane
- xmab20717
- xmab22841
- cnsi-fe(ii)
- hryz-t101
- stimotimagene copolymerplasmid
- tsc-204-a0201
- tsc-200-a0201
- tsc-203-a0201
- [177lu]lu-akir001
- scg142 tcr-t cells
Other trials (4)
Organizations
Organization Involved with Phase 3 Indications (8)
Organization Involved with Phase 2 Indications (21)
- AstraZeneca
- Genentech
- Inovio Pharmaceuticals
- Tarveda Therapeutics
- Burzynski Research Institute
- Harvard University
- Duke University
- University of Washington
- NRG Oncology
- Southwest Oncology Group
- UNICANCER
- Utrecht University
- University of Minnesota
- Netherlands Cancer Institute
- Curie Institute
- European Organisation for Research and Treatment of Cancer
- University of Texas at Houston
- Gynecologic Oncology of Indiana
- Fondation ARC
- Lowell General Hospital
- Saint Anne's Hospital
Organization Involved with Phase 1 Indications (6)
Organization Involved with Other Experimental Indications (2)